Published in Breast Cancer Res Treat on May 20, 2014
A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer | NCT03559803
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol (2015) 1.62
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol (2015) 1.45
T-cell exhaustion in the tumor microenvironment. Cell Death Dis (2015) 1.32
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res (2015) 1.29
Unvalidated antibodies and misleading results. Breast Cancer Res Treat (2014) 1.17
Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) (2015) 1.14
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol (2015) 1.05
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med (2015) 1.04
Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer (2015) 1.03
Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol (2015) 1.02
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res (2015) 1.01
Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer (2015) 1.00
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget (2015) 0.99
Immune checkpoint inhibitors in clinical trials. Chin J Cancer (2014) 0.98
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget (2015) 0.98
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw (2014) 0.96
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget (2016) 0.89
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci (2016) 0.88
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer (2016) 0.88
Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. PLoS One (2016) 0.87
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget (2016) 0.86
The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol (2016) 0.85
Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) (2014) 0.85
Breast Cancer Update 2014 - Focus on the Patient and the Tumour. Geburtshilfe Frauenheilkd (2015) 0.85
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.84
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res (2015) 0.83
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer (2015) 0.83
Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol (2015) 0.83
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol (2016) 0.83
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. J Transl Med (2016) 0.82
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Transl Oncol (2016) 0.82
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget (2016) 0.82
Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Res (2016) 0.81
The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. Oncoimmunology (2015) 0.80
Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel) (2016) 0.80
PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays. Int J Mol Sci (2016) 0.79
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. BMC Cancer (2016) 0.79
Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.79
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. Front Oncol (2015) 0.79
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. Int J Mol Sci (2017) 0.78
GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression. J Pathol Transl Med (2017) 0.77
Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol (2016) 0.77
PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes. Oncotarget (2017) 0.77
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open (2017) 0.76
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology (2016) 0.76
CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget (2016) 0.75
Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Oncotarget (2016) 0.75
Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer (Dove Med Press) (2016) 0.75
Emerging therapies for breast cancer. J Hematol Oncol (2017) 0.75
A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther (2017) 0.75
Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. J Breast Cancer (2016) 0.75
Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors. Oncotarget (2017) 0.75
Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. Hum Vaccin Immunother (2016) 0.75
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nat Commun (2017) 0.75
Predictive factors of tumor immune microenvironment for long-term follow-up in early stage breast cancer. Cancer Sci (2016) 0.75
Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. PLoS One (2017) 0.75
Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine (Baltimore) (2017) 0.75
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer (Auckl) (2015) 0.75
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget (2017) 0.75
Mammaglobin-A is a target for breast cancer vaccination. Oncoimmunology (2016) 0.75
Author's response to "Letter to the editor: unvalidated antibodies and misleading results". Breast Cancer Res Treat (2014) 0.75
Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB. Oncotarget (2017) 0.75
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther (2017) 0.75
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol (2017) 0.75
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Sci Rep (2017) 0.75
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol (2017) 0.75
PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget (2017) 0.75
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clin Cancer Res (2017) 0.75
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget (2017) 0.75
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Curr Oncol Rep (2017) 0.75
PD-L1 and intratumoral immune response in breast cancer. Oncotarget (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Molecular portraits of human breast tumours. Nature (2000) 94.14
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol (1989) 7.69
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med (1985) 5.82
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer (2010) 5.05
Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol (2001) 3.09
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol (2010) 3.06
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res (2009) 2.97
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer (2013) 2.75
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res (2014) 2.68
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother (2004) 2.42
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res (2013) 2.30
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2013) 1.84
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer (2008) 1.63
Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer (2007) 1.53
PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One (2014) 1.46
PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One (2013) 1.39
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother (2010) 1.37
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23
HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol (2004) 1.15
Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets (2011) 1.12
Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol (2006) 1.12
Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer (2012) 1.01
Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett (2005) 0.94
Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta (2004) 0.93
Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One (2012) 0.91
Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol (2005) 0.88
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Timing the ancestor of the HIV-1 pandemic strains. Science (2000) 10.42
HIV-1 nomenclature proposal. Science (2000) 6.61
Hel-N1: an autoimmune RNA-binding protein with specificity for 3' uridylate-rich untranslated regions of growth factor mRNAs. Mol Cell Biol (1993) 4.63
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy (2009) 2.84
Perforator stroke after elective stenting of symptomatic intracranial stenosis. Neurology (2006) 2.82
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Virtual Cell modelling and simulation software environment. IET Syst Biol (2008) 2.43
Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. J Virol (1992) 2.36
Prehension synergies: effects of object geometry and prescribed torques. Exp Brain Res (2002) 2.29
Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses (2001) 2.23
In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax (2007) 2.09
Does the prophylactic administration of magnesium sulphate to patients undergoing thoracotomy prevent postoperative supraventricular arrhythmias? A randomized controlled trial. Br J Anaesth (2011) 2.08
Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry (2001) 2.08
Disruption of the telomerase catalytic subunit gene from Arabidopsis inactivates telomerase and leads to a slow loss of telomeric DNA. Proc Natl Acad Sci U S A (1999) 1.99
Wild Mandrillus sphinx are carriers of two types of lentivirus. J Virol (2001) 1.96
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer (2010) 1.96
Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer (2009) 1.95
Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation (1999) 1.93
Origins and evolution of AIDS viruses: estimating the time-scale. Biochem Soc Trans (2000) 1.90
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2013) 1.84
Identification of a proline residue as a transduction element involved in voltage gating of gap junctions. Nature (1993) 1.79
Origins and evolution of AIDS viruses. Biol Bull (1999) 1.77
Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology (2000) 1.76
Methicillin resistant Staphylococcus aureus in the critically ill. Br J Anaesth (2004) 1.75
Natural infection of a household pet red-capped mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virus. J Virol (1998) 1.66
Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. Proc Natl Acad Sci U S A (1999) 1.63
Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. Neurology (2001) 1.62
Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. J Virol (1997) 1.62
The Toronto traumatic brain injury study: injury severity and quantified MRI. Neurology (2008) 1.61
The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer (1996) 1.61
Variations in the survival of adult cancer patients in Italy. Tumori (1997) 1.60
Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem (2001) 1.60
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology (2001) 1.58
Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. Colorectal Dis (2012) 1.56
Seasonality of suicide in Singapore: data from the equator. Psychol Med (2001) 1.54
Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol (1998) 1.53
Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis (2000) 1.52
Factors influencing survival rate in adenoid cystic carcinoma of the salivary glands. Int J Oral Maxillofac Surg (1997) 1.52
Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. J Clin Microbiol (1999) 1.51
Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol (2012) 1.49
Effect of outdoor airborne particulate matter on daily death counts. Environ Health Perspect (1995) 1.49
A prospective, multicentre, observational cohort study of analgesia and outcome after pneumonectomy. Br J Anaesth (2011) 1.48
Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol (1997) 1.45
Precambrian animal diversity: putative phosphatized embryos from the Doushantuo Formation of China. Proc Natl Acad Sci U S A (2000) 1.44
Detection of a novel and highly divergent coronavirus from asian leopard cats and Chinese ferret badgers in Southern China. J Virol (2007) 1.44
Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J (2001) 1.42
Functional architecture of synapses in the inner retina: segregation of visual signals by stratification of bipolar cell axon terminals. J Neurosci (2000) 1.39
The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res (2000) 1.38
Biochemical markers of cerebral damage. Eur J Anaesthesiol (1997) 1.36
Prolonged intercostal nerve blockade in sheep using controlled-release of bupivacaine and dexamethasone from polymer microspheres. Anesthesiology (1998) 1.36
Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer (2001) 1.34
Dark matter results from 225 live days of XENON100 data. Phys Rev Lett (2012) 1.31
Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. AIDS Res Hum Retroviruses (2002) 1.28
In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax (2006) 1.27
European health systems and cancer care. Ann Oncol (2003) 1.27
Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer (2003) 1.26
Remote spatial memory in an amnesic person with extensive bilateral hippocampal lesions. Nat Neurosci (2000) 1.26
Mammographic parenchymal patterns and risk of breast cancer at and after a prevalence screen in Singaporean women. Int J Epidemiol (2000) 1.25
Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res (2001) 1.25
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J Virol (1996) 1.22
Functional analysis of the simian immunodeficiency virus Vpx protein: identification of packaging determinants and a novel nuclear targeting domain. J Virol (2001) 1.20
Differential methylation of the TRPA1 promoter in pain sensitivity. Nat Commun (2014) 1.19
Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem (2001) 1.18
A cohort study on mortality among wives of workers in the asbestos cement industry in Casale Monferrato, Italy. Br J Ind Med (1993) 1.17
Modeling the functional genomics of autism using human neurons. Mol Psychiatry (2011) 1.17
Dark matter results from 100 live days of XENON100 data. Phys Rev Lett (2011) 1.16
Mechanically gated channel activity in cytoskeleton-deficient plasma membrane blebs and vesicles from Xenopus oocytes. J Physiol (2000) 1.15
Birthplace and classic Kaposi's sarcoma in Italy. Associazione Italiana Registri Tumori. J Natl Cancer Inst (1995) 1.15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J Med Chem (2001) 1.14
A genetic linkage map of grape, utilizing Vitis rupestris and Vitis arizonica. Theor Appl Genet (2004) 1.12
Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. J Virol (1997) 1.12
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene (2011) 1.11
PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep (2007) 1.11
Review of 1375 enucleations in the TongRen Eye Centre, Beijing. Eye (Lond) (2007) 1.10
Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX. J Biol Chem (2001) 1.09
Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression. Scand J Immunol (2007) 1.09
Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction. Am J Physiol Gastrointest Liver Physiol (2001) 1.09
Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer (1998) 1.08
Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes. Br J Cancer (2002) 1.08
Oxidative stress contributes to methotrexate-induced small intestinal toxicity in rats. Scand J Gastroenterol (2004) 1.07
Mammographic density and its interaction with other breast cancer risk factors in an Asian population. Br J Cancer (2011) 1.07
Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg (2000) 1.06
Expression of membrane proteins from Mycobacterium tuberculosis in Escherichia coli as fusions with maltose binding protein. Protein Expr Purif (2006) 1.06
Cancer risk and social inequalities in Italy. J Epidemiol Community Health (1994) 1.05
Parallel risk assessment of melanoma and basal cell carcinoma: skin characteristics and sun exposure. Melanoma Res (1998) 1.05
EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer (2013) 1.04
Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor. Biochem Soc Trans (2007) 1.03
Social class and cancer survival in Turin, Italy. J Epidemiol Community Health (1997) 1.03
Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem (2001) 1.03
Antineoplastic agents. 278. Isolation and structure of axinastatins 2 and 3 from a western Caroline Island marine sponge. J Med Chem (1994) 1.03
Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. J Nat Prod (1996) 1.03
Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? Eur J Surg Oncol (2012) 1.03
Activation of interleukin-6/STAT3 and liver regeneration following transplantation. J Surg Res (2001) 1.02
Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther (2001) 1.02